Anti-NFkB p105 / p50 antibody
Specifications
| Product Cat#: | AB-06-3125 |
| Product type: | Primary antibody |
| Antigen: | NFkB p105 / p50 |
| Immunogen: | This antibody is produced by immunizing mice with a synthetic peptide (KLH-coupled) corresponding to NF-κB p105/p50. |
| Species immunized: | Mouse |
| Isotype: | IgG |
| Applications: | Western Blot (1:200-1:2000); Immunocytochemistry (1:100-1:200); Immunohistochemistry |
| Reactivity: | Mouse, Rat and Human |
| Clonality (clone number): | Monoclonal(A2-7) |
| Form: | Liquid |
| Buffer: | 1*TBS (pH7.4), 1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 2 mg/ml |
| Purity: | Protein Aaffinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | DKFZp686C01211 antibody |
| DNA binding factor KBF1 antibody | |
| DNA binding factor KBF1 EBP1 antibody | |
| DNA-binding factor KBF1 antibody | |
| EBP 1 antibody | |
| EBP-1 antibody | |
| EBP1 antibody | |
| KBF1 antibody | |
| MGC54151 antibody | |
| NF kappa B antibody | |
| NF kappaB antibody | |
| NF kappabeta antibody | |
| NF kB1 antibody | |
| NFkappaB antibody | |
| NFKB 1 antibody | |
| NFKB p105 antibody | |
| NFKB p50 antibody | |
| Nfkb1 antibody | |
| NFKB1_HUMAN antibody | |
| Nuclear factor kappa B DNA binding subunit antibody | |
| Nuclear factor kappa-B, subunit 1 antibody |
Target information
F-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5′-GGRNNYYCC-3′, located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.
Provider
Erpantech Laboratory
